Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
NCT07485062 on ClinicalTrials.gov · last registry update 2026-08-20
An unusually large phase 4: 164 participants, more than double the 75 typical for the stage. Due to report 1 May 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Trail Making Test (TMT) Part A and B. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Western University, Canada
- Sponsor type
- Other
- Enrollment
- 164
- Started
- 2026-09-01
- Primary completion
- 2029-05-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Trail Making Test (TMT) Part A and B
Conditions studied
Type 2 Diabetes · Cognitive Decline in Older Adults
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.